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NeuroprotectionAccording to World Health Organization estimates, type 2 diabetes (T2D) is an epidemic (particularly in
under development countries) and a socio-economic challenge. This is even more relevant since increasing
evidence points T2D as a risk factor for Alzheimer's disease (AD), supporting the hypothesis that AD is a
“type 3 diabetes” or “brain insulin resistant state”. Despite the limited knowledge on the molecular mecha-
nisms and the etiological complexity of both pathologies, evidence suggests that neurodegeneration/death
underlying cognitive dysfunction (and ultimately dementia) upon long-term T2D may arise from a complex
interplay between T2D and brain aging. Additionally, decreased brain insulin levels/signaling and glucose
metabolism in both pathologies further suggests that an effective treatment strategy for one disorder may
be also beneﬁcial in the other. In this regard, one such promising strategy is a novel successful anti-T2D
class of drugs, the glucagon-like peptide-1 (GLP-1) mimetics (e.g. exendin-4 or liraglutide), whose potential
neuroprotective effects have been increasingly shown in the last years. In fact, several studies showed that,
besides improving peripheral (and probably brain) insulin signaling, GLP-1 analogs minimize cell loss and
possibly rescue cognitive decline in models of AD, Parkinson's (PD) or Huntington's disease. Interestingly,
exendin-4 is undergoing clinical trials to test its potential as an anti-PD therapy. Herewith, we aim to inte-
grate the available data on the metabolic and neuroprotective effects of GLP-1 mimetics in the central ner-
vous system (CNS) with the complex crosstalk between T2D-AD, as well as their potential therapeutic
value against T2D-associated cognitive dysfunction.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Diabetes mellitus is one of the most common metabolic diseases
and a major disorder of insulin regulation that nowadays constitutes
an epidemic [1–3]. In this regard, in 2004, Wild et al. [4] estimated
that 171 million people worldwide (~3% of the population) were
diabetic. More recent estimations pointed to 366 million diabetics in
2011, a number that will rise to 552 million by 2030 [5]. However,
these numbers are somehow controversial, given the World Health
Organization's prediction of ~300 million diabetics worldwide in
2025 [6]. Despite this controversy, what remains unquestionable is+ 351 239 822776.
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rights reserved.that this pathology constitutes an important public health concern
in 21st century, especially concerning type 2 diabetes (T2D).
Regarding T2D, estimates point to ~6% of adults worldwide affected
by this disease, that also accounts for 90–95% of diabetes cases [3]. This
scenario is further aggravated by the fact that T2D is becoming more
common in young people, challenging the idea that it usually occurs in
people over >30 years [7]. Moreover, the increased prevalence of T2D
with aging, the co-occurrence of risk factors associated withmodern life-
style in developed and under development countries (e.g. increased lon-
gevity, obesity, sedentarism, hypertension) and the global crisis (with a
negative impact in lifestyle and healthcare systems), currently renders
this disease a heavy socio-economic burden [1,2]. Last, but not the least,
chronic T2D and its long-term complications (e.g. peripheral and auto-
nomic neuropathy, stroke, retinopathy, cardiovascular disease, renal fail-
ure) also have a signiﬁcant impact in quality of life, aswell as inmorbidity
and mortality of these patients [1,2].
Therefore, early diagnosis of T2D, improvement of glycemic control
and a proactive prevention of its complications, together with efﬁcient
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against this epidemic. The achievement of these goals will reduce sub-
stantially T2D ﬁnancial impact, especially in western countries [1,2].
In this review,wewill focus on the negative impact of chronic T2D in
central nervous system (CNS), with a special emphasis on neurodegen-
erative diseases of the dementia-type (e.g. Alzheimer's disease (AD)),
and the increasingly promising therapeutic potential of a new class of
anti-T2D drugs, the incretin/glucagon-like peptide-1 (GLP-1) mimetics
(particularly the most well-studied exendin-4), against T2D-associated
neurodegeneration.
1.1. When long-term T2D crosstalks with brain function: a general overview
on the affected molecular mechanisms
Although the etiology of type 1 diabetes (T1D) is well known and in-
volves an absolute deﬁciency of insulin, T2D is a highly complex, multi-
factorial metabolic disease, characterized by a progressive β-cell failure
(relative insulin deﬁciency), decreased insulin action and insulin resis-
tance [2,7]. Additionally, T2D develops under a cluster of risk factors
that includes high blood glucose, obesity, increased blood triacylglycerols
and insulin resistance,which individually or collectively, also increase the
risk for neurodegeneration/neuronal death, and functional and structural
brain changes, culminating in cognitive dysfunction that underlies some
dementia-type disorders (e.g. AD) [7,8].
Indeed, diabetes has been widely associated with slowly progressive
brain damage [9,10] resulting in diabetic neuropathy and/or mild to
moderately impaired cognitive function. Although both T1D and T2D
patients seem to be affected by cognitive alterations, these are mostly
clinically relevant in the elderly T2D [11]. Interestingly, despite the
body weight gain often associated to T2D, cognitive dysfunction seems
to correlate with a pronounced brain atrophy (particularly in cortical,
subcortical and hippocampal areas) and, subsequently, decreased
brain weight, as well as white matter abnormalities in these patients
[12–20]. Noteworthy, T2D has been also described to inﬂuence the sur-
vival of AD patients and to increase the incidence of stroke, Parkinson's
disease (PD) and several other neurological disorders [1,12,21].
Despite the limited knowledge on the molecular mechanisms un-
derlying chronic damage in T2D CNS, it has been hypothesized that a
complex interaction between this pathology and brain aging may
occur, involving a multitude of mechanisms [1,11]. These include a
defective insulin action, metabolic/mitochondrial dysfunction, oxida-
tive stress, advanced glycation endproducts (AGEs) formation, in-
creased aldose reductase activity, activated protein kinase C (PKC)
and increased hexosamine pathway ﬂux [1]. Herewith, we will brieﬂy
discuss the involvement of some of these mechanisms in the patho-
genesis of long-term complications affecting T2D CNS.
1.1.1. Defective insulin action and its long-term consequences in T2D
brain
Chronic peripheral hyperinsulinemia and insulin resistance are
some of the main consequences of diabetes (especially T2D-related
insulin resistance), leading to a downregulation of brain insulin up-
take and its subsequent deprivation from the crucial beneﬁcial
effects of this hormone [22]. Indeed, the classic idea that CNS was
insulin-insensitive and the hormone was unable to cross the blood–
brain barrier (BBB), has been widely challenged in the last three de-
cades [21,23,24], with accumulating evidence showing that insulin
can reach high levels in brain [25,26] and exert long-term neuronal
trophic effects [27].
It has beenwidely described thatmost of the insulin present in adult
CNS derives primarily from pancreatic β-cells, being transported into
the brain by the cerebrospinal ﬂuid (CSF) and crossing the BBB via a
carrier-mediated, saturable, regulatable, and temperature-sensitive ac-
tive process. Therefore, it is not surprising that an acute peripheral
hyperinsulinemia episode increases CSF insulin content [1,11,28]. On
the other hand, chronic peripheral hyperinsulinemia (as in insulinresistance or T2D) downregulates BBB insulin receptors (IR) and
impairs brain insulin uptake [11]. Additionally, insulin resistance and
glucose dysmetabolism in uncontrolled T2D may also decrease
cerebral blood ﬂow and oxidative glucose metabolism, probably
via downregulation of neuronal insulin signaling (inhibition of IR
phosphorylation) and glycolytic enzymes [1]. As a consequence, brain
activity is rapidly affected (independently from any systemic effects),
leading to progressively impaired learning, memory and cognition
[29–31]. Similar results were observed in healthy individuals submitted
to a hyperinsulinemic-euglycemic clamp [32] and in the streptozotocin
(STZ)-induced T1D rat model, in which cognitive dysfunction was cor-
related with impaired hippocampal plasticity [33]. Additionally, Li et
al. [34] suggested that impaired cognition could arise from impaired
hippocampal insulin/insulin-like growth factor-1 (IGF-1) action and
subsequent neuronal apoptosis. This hypothesis was further supported
by the studies from Sima and Li [35] reporting that restoration of insulin
signaling by the proinsulin C-peptide prevented those deleterious ef-
fects of T1D. However, a comparison of T2D versus T1D rats (BBZDR/
Wor versus. BB/Wor rats, respectively) showed that neuronal loss,
neurite degeneration, impaired amyloid precursor protein (APP) me-
tabolism, increased hyperphosphorylated tau protein (P-Tau) and dys-
functional insulin/IGF-1 signalingweremore severe in T2D, probably as
a result of insulin resistance [36].
Besides insulin entry into the CNS via a carrier-mediated system,
an alternative pathway involves its direct diffusion through the area
postrema, a circumventricular region with a “leaky” BBB [37,38].
Furthermore, it has been alsowidely proposed that insulin can be synthe-
sized de novo in brain (particularly in pyramidal neurons, e.g., from hip-
pocampus, prefrontal cortex, entorhinal cortex, and olfactory bulb, but
not in glial cells) [29], being then released by exocytosis [39]. This is con-
sistentwith reports that insulin is highly enriched in brain cortex, olfacto-
ry bulb, hippocampus, hypothalamus, and amygdala [40]. Herewith,
insulin and IR-mediated signaling pathways (together with the insepara-
ble IGF-1/IGF-1 receptor (IGF-1R)) seem to play a crucial role in the
regulation of CNS metabolism, neuronal growth and differentiation,
neuromodulation and neuroprotection [1].
Insulin iswidely knownas a peripheral regulator of glucose transport
andmetabolism [27,41,42], which involve a complex crosstalk between
peripheral nutritional and other hormonal signals and specialized CNS
neurons (the glucosensing neurons) from the hypothalamic arcuate nu-
cleus. Besides expressing and responding to peripheral insulin and
leptin (hormones that inform the brain regarding the peripheral meta-
bolic and adiposity status), these glucosensing neurons were also
shown to detect and respond to the very small decreases in glycemia
that precede a meal in both humans and rodents [43]. And, depending
on glucose levels, insulin can centrally regulate the ingestive behavior
and energy homeostasis, via differential effects on glucosensing neuro-
nal membrane potential [43,44], with low extracellular glucose levels
promoting the activity of glucose-inhibited neurons (a subtype of
glucosensing neurons), while high glucose levels increase the activity
of the glucose-excited glucosensing neurons by closing their K+ATP
channels [45]. Although the mechanisms involved herein are not
completely understood, the anorexigenic effect of brain insulin signaling
may be mediated by the activation of insulin receptor substrate (IRS)/
phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway in rat hy-
pothalamic arcuate nucleus. As a result, K+ATP channels are activated
and opened, probably due to 1) phosphatidylinositol 3,4,5-trisphos-
phate (PIP3) binding to K+ATP channel, lowering the ability of ATP
to inhibit them, 2) a direct inhibition of ATP binding to the channel
by PIP3, or 3) a PIP3-induced degradation of actin ﬁlaments around
channels, a process in which Rho and Rac GTPases are likely candi-
dates [46,47]. As K+ATP channels are opened, glucosensing neurons
become hyperpolarized and inactive and neuronal ﬁring is reduced,
inhibiting the secretion of the orexigenic neuropeptide Y (NPY)/
agouti-related protein (AgRP) and decreasing food intake and body
weight [46,47]. To further complicate this system, it has been
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orexigenic proopiomelanocortin (POMC) neurons, but as orexigenic
NPY andAgRP cells aremore potent, thiswill culminate in a net catabol-
ic response [47]. Moreover, besides regulating body weight homeosta-
sis, hypothalamic insulin signaling also controls peripheral glucose
production and utilization, in a process that may also involve its action
on CNS K+ATP channels [47]. More speciﬁcally, insulin-induced K+ATP
channel activation at the level of mediobasal hypothalamus and subse-
quent activation of brain stem nuclei generates efferent vagal input to
hepatocytes, inhibiting hepatic glucose output into bloodstream and
decreasing blood glucose levels [48]. Once impaired, hypothalamic in-
sulin signaling (and hypothalamus-liver axis) culminates in a decreased
hepatic sensitivity to the circulating hormone and, subsequently, stimu-
lates glucose production by the liver [46,49,50].
Interestingly, it has been suggested that impaired CNS insulin signal-
ing arising from peripheral insulin resistance may have an orexigenic
effect, increasing body weight [46]. In this regard, disruption of insulin
receptor autophosphorylation and subsequent inhibition of IRS-1 and
−2 phosphorylation and association with PI3K/Akt were described in
the hypothalamus of obese rats [51]. Similarly, impaired brain insulin
signaling associated to peripheral insulin resistance also leads to phos-
phorylation of IRS-1 at serine (Ser)/threonine (Thr) residues (instead
of “traditional” tyrosine residues) by IRS kinases, blocking SH2 domain
binding to IRS-1 and thereby inhibiting downstream insulin signaling
and possibly constituting a negative feedback mechanism [52]. For
instance, insulin resistance-mediated activation of c-Jun N-terminal
kinase (JNK) promotes IRS-1 phosphorylation at Ser307 and, as this
residue is adjacent to IRS-1 phosphotyrosine-binding (PTB, receptor-
binding) domain, its phosphorylation hampers the interaction IR-IRS-1
and subsequent Tyr phosphorylation of IRS-1 [52], therefore limiting
insulin action on body weight which, in turn, will be controlled by the
orexigenic modulators NPY/AgRP and γ-aminobutyric acid (GABA),
culminating in increased body weight [46,47,53]. Surprisingly, chronic
insulin-induced phosphorylation of IRS-1 at Ser307 has been also pro-
posed to mediate, at least partially, IRS-1 degradation and point also to
a possible protective role for Ser phosphorylation [52]. However, data
on this positive effect in the context of insulin resistance, diabetes or obe-
sity are scarce and the underlying mechanisms elusive.
From the above-mentioned, it is evident that brain requires robust
neuroendocrine counterregulatory mechanisms to maintain periph-
eral glucose levels within a narrow, non-deleterious range.
Although the involvement of CNS insulin in the control of peripheral
glucose metabolism is becoming increasingly unraveled, its participa-
tion in the regulation of brain glucosemetabolism is still a matter of de-
bate. Indeed, after the traditional idea that brain glucose metabolism
was essentially insulin insensitive [54], a hypothesis arose that it
could be regulated by insulin only in glial cells [55–57]. More recently,
it has been proposed that neuronal insulin/IR signaling cascades may
control overall cerebral glucose metabolism [27,58–60]. Increasing evi-
dence supports this hypothesis, namely: 1) the overlapping distribu-
tions of insulin, IR, and glucose transporters (GLUTs) isoforms 1 and 4
in selective brain regions (e.g., hippocampus and choroid plexus) [61],
2) modulation of cerebellar GLUT4 expression by changes in circulating
insulin levels [62] and 3) brain regional changes in glucose utilization
upon hyperinsulinemia in rodents [63]. However, themost unequivocal
supporting evidence was that fasting insulin levels can maximally
stimulate brain cortical glucose metabolism in humans, and that the
insulin-induced increment in glucose uptake may involve the recruit-
ment of the partially insulin-sensitive glial GLUT1 to the plasma mem-
brane [64].
An alternative source of neuronal glucose seems to involve
insulin-mediated inhibition of neuronal norepinephrine uptake, sub-
sequent activation of glial β-adrenoreceptors and release of astrocytic
glycogen that can be converted into glucose, which is then transported
via the insulin-sensitive GLUT1 to the extracellular milieu for neuronal
use [27,54,65]. Therefore, the crosstalk between CNS insulin levels/action and glucose metabolism has to be tightly regulated, to avoid
any deleterious changes that might affect energy production and
neuronal survival [66]. Accordingly, we previously reported that
insulin-induced neuronal IR/IGF-1R activation under oxidative stress
and subsequent PI3K/Akt-mediated signaling prevented GLUT3
oxidation, restored glucose uptake and hexokinase-II expression, re-
covering neuronal glycolysis and energy levels [67,68]. Additionally,
other authors suggested that insulin-induced antioxidant defenses in
T1D could protect against GLUT oxidation and stimulate intracellular
metabolism [69]. Nevertheless, there are also reports where insulin
appears not to interfere with acute glucose transport into the brain
[70,71], rendering this issue somehow still controversial.
Given the previously referred heterogenous distribution of brain IR,
poor correlation between IR location and neuronal energy utilization,
the insulin-independent neuronal glucose uptake, its neuromodulatory
role in invertebrates, its action on neuronal norepinephrine and seroto-
nin uptake, and its relation to NPY, it is not surprising that insulin may
play other roles at CNS rather than metabolic regulation [27,61]. These
include increased neurite outgrowth, regeneration of small myelinated
ﬁbers, maintenance of cortical, sympathetic and sensory neuronal
survival during nervous system development, stimulation of neuronal
protein synthesis, and improvement of synaptic activity and plasticity,
memory formation, and storage, as well as neuroprotection [1,11].
In accordance with the above-mentioned studies regarding the
negative effects of T2D-associated insulin resistance in CNS, insulin
therapy has been shown to improve memory/learning in rats [46]
and in healthy humans (upon intranasal administration), notably
without changes in peripheral glycemia [32,72]. Additionally, system-
ic insulin infusion also improved verbal memory and attention [73].
And, in previous studies, we also showed that insulin restores synap-
tosomal GABA and glutamate uptake and extrasynaptosomal levels in
rats submitted to oxidative stress and/or T2D [74,75]. These effects
could be due to insulin's direct effect on neurotransmitter transport
and/or to decreased ATP levels and subsequent reversal of the
amino acid transporters under such conditions, thus protecting neu-
rons against damaging effects of excitotoxicity or oxidative stress
[74,75].
1.1.1.1. Impaired insulin signaling as the potential missing link between
T2D and AD. Similarly to T2D, impaired insulin function has been
also increasingly demonstrated in AD, suggesting that decreased
brain insulin levels/action may constitute the missing link between
both pathologies [1]. More speciﬁcally, several authors suggested
that a prolonged peripheral hyperinsulinemia could impair the BBB
and insulin transport into CNS, thus affecting IR activity and culminat-
ing in a brain insulin-resistance that could explain the lower insulin
levels in CSF of AD patients [76,77]. Moreover, de la Monte and
Wands [78] proposed that such disruption in brain insulin signaling
could underlie the AD-associated neurodegeneration and cognitive
decline. A hypothesis further supported by reports of: 1) decrement
in insulin levels and IR expression in AD brain, 2) inverse correlation
between AD Braak stage and levels of insulin, IGF-1 and−2 and their
receptors, 3) decreased insulin clearance and increased amyloid-β
(Aβ) levels in AD patients, 4) disrupted brain insulin function upon
intracerebroventricular (icv) injection of STZ (a model of AD) that
resulted in several features of human AD, and 5) memory restoration
in AD patients upon insulin-glucose therapy [18]. Importantly,
T2D-associated hyperinsulinemia has been also shown to increase
Aβ peptide accumulation (a pathological hallmark of AD), due to
the competition between insulin and Aβ for insulin degrading
enzyme (IDE, a major Aβ-degrading enzyme) and its subsequent inhibi-
tion [79,80]. On the other hand, ADmice submitted to diet-induced insu-
lin resistance and hyperinsulinemia, as well as the non-obese T2D
Goto-Kakizaki (GK) rat brain, also showed increased Aβ accumulation
and decreased IDE levels [81,82]. And similar results were described
for ADpatientswith brain insulin resistance [83]. Studies fromQuerfurth
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from patients with dementia and hyperglycemia also displayed hip-
pocampal damage, increased P-Tau protein and glycogen synthase
kinase-3β (GSK-3β) upregulation. Together with IDE-mediated Aβ
degradation, insulin has been also shown to modulate γ-secretase
activity and enhance Aβ trafﬁcking from the endoplasmic reticulum
and trans-Golgi network (the main sites for Aβ formation) to the
plasmamembrane, thereby increasing its extracellular levels [85,86].
Nevertheless, Kroner [87] proposed that, rather than hyper-
insulinemia, it is the co-existence of brain insulin resistance and insu-
lin deﬁciency that may underlie AD pathology. In this regard, AD
could be faced as a brain-speciﬁc type of diabetes, the type 3 diabetes
[87]. Interestingly, in a very recent study, Talbot et al. [88] showed
that, despite no evident features of diabetes, AD brain is insulin and
IGF-1 resistant, with dysfunctional IRS-1 mediating insulin resistance,
whilst impaired IRS-2 underlying IGF-1 resistance. These authors
also proposed that brain insulin resistance may be due (at least in
part) to peripheral insulin resistance, reduced brain insulin uptake
and increased brain Aβ oligomers. Conversely, brain IGF-1 resistance
in AD (and subsequent impairment in IGF-1 signaling via IRS-2)
could be an adaptive mechanism to delay Aβ accumulation and toxic-
ity, as seen in animal models of AD [88].
Besides regulating Aβ levels, insulin also controls the other neuro-
pathological hallmark of AD: P-Tau, thus reinforcing its role as the
potential missing link between diabetes and AD [18,89]. Indeed, both pe-
ripheral hyperinsulinemia and CNS insulin resistance have been widely
shown to modulate tau phosphorylation [18]. For example, Cheng et al.
[90] reported that loss of IGF-1 signaling increased P-Tau and neuroﬁbril-
lary tangles (NFTs) formation. But themore striking observations include
the detection of NFTs in hippocampus of IRS-2-knockout mice (a model
of T2D) [91] and increased P-Tau levels in NIRKO mice (a model with
neuronal/brain-speciﬁc deletion of IR) [92]. However, given the different
patterns of tau protein phosphorylation between the two animalmodels,
the authors proposed that it could bemediated by both insulin resistance
and hyperinsulinemia. Accordingly, Schubert et al. [92] observed that
such increased P-Tauwas due to the loss of insulin-mediated PI3K activa-
tion and subsequent impairment in the phosphorylation of both Akt and
GSK-3β. Similarly, Jolivalt et al. [93] reported that a mouse model of T1D
administered with insulin at the onset of the disease recovered learning
skills and had less accumulated P-Tau in brain, probably due (at least par-
tially) to the restoration of GSK-3β phosphorylation. More recently, the
same authors demonstrated that impaired IR activity and increased
GSK-3βwere associated with an increment in P-Tau levels and in senile
plaque formation in brains from APP transgenic mice with features of
T1D [94]. Freude et al. [32] also found that peripherally-injected insulin
directly targets the brain, rapidly initiating IR-mediated signaling path-
ways that culminate in site-speciﬁc tau protein phosphorylation. Similar
resultswere previously obtained in cultured neurons treatedwith insulin
or IGF-1 [95]. Therefore, results suggest that the increased incidence of
AD in diabetic patients may also arise from the dysregulation of tau
protein phosphorylation mechanisms under hyperglycemia and insulin
resistance [18].
Of note is the fact that themechanisms underlying the effects of T1D
and T2D in AD pathology (and, more speciﬁcally, in P-Tau accumula-
tion) may be different, with insulin deﬁciency playing the major role
in increased P-Tau in T1D,while a cluster of hyperglycemia- plus insulin
resistance-mediated increased P-Tau may be the major players in T2D
[96]. However, Talbot et al. [88] suggested that tau pathology may not
be essential for the development of brain insulin resistance in AD.
From the above-mentioned, it is not surprising that insulin has been
increasingly faced as the potential missing link between chronic diabetes
(particularly T2D) and dementia-type neurodegenerative diseases (as
AD) [9,10], mostly due to its roles in the regulation of Aβ and tau protein
“dynamics” in the brain. However, this hormone also plays a crucial role
in several other brain functions, including cognition, memory and synap-
tic plasticity [97] (as previously discussed). Accordingly, insulin therapy(at doses that do not affect hyperglycemia) has been shown to restore
biochemical and pathological features of peripheral sensory neuropathy
in animalmodels of T1D [59]. Besides this, insulin treatment also restores
cognitive function in diabetic patients [50,98,99]. And, last but not the
least, tissue (and cellular) dependence on insulin is such that its restric-
tion under damaging conditions culminates in cell atrophy and apoptotic
death [59]. In this regard, Soeda et al. [100] reported that mutating the
SH2-containing inositol 5′-phosphatase 2 (SHIP2, a negative regulator
of phosphatidylinositol 3,4,5-trisphosphate-mediated signals) in neu-
rons promoted insulin signaling and ameliorated hippocampal synaptic
plasticity and memory formation, while SHIP2 overexpression in
mice impaired Akt-mediated IR/IGF-1R signaling and attenuated the
neuroprotection afforded by insulin/IGF-1, culminating in neuronal ap-
optosis andmemory impairment [100]. These authors also demonstrat-
ed that SHIP2 levels were increased in T2D db/dbmice brain [100].1.1.2. Impaired glucose metabolism/mitochondrial function in T2D brain
Together with decreased insulin action upon T2D, disruption of
brain glucose metabolism (which may be also due to impaired glucose
transport across BBB) seems to impair cerebral blood ﬂowand oxidative
glucose metabolism [30,101–103].
As extremely metabolically-active cells, neurons have high energy
demands for synaptic transmission, axonal/dendritic transport, and ion
channels/pump activity. Therefore, neuronal function and survival are
highly affected by changes in brain glucose metabolism (including glu-
cose supply, transport and utilization) [11,104]. This is further aggravated
by neuronal inability to synthesize or store glucose, rendering themhigh-
ly dependent on its transport across the BBB via GLUTs [105]. Thus, it is
not surprising that increasing evidence points toward a correlation be-
tween insulin resistance, brain glucose dysmetabolism, synaptic function
andmemory deﬁcits in both pre-diabetic and T2D [106,107]. Interesting-
ly, we recently reported an increased accumulation of Aβ and P-Tau in
sucrose-treated mouse brain (with metabolic alterations resembling
those of T2D), further suggesting that (pre)diabetesmight be a risk factor
for AD [7]. Similar results were reported by others in both T1D and T2D
rat brain, being more pronounced in T2D [36]. Taken together, these re-
sults favor the idea that amyloidogenesis (the transformation of a soluble
protein into insoluble ﬁbrillar protein aggregates) [108] could constitute
a valid and reliable pathological hallmark to both AD and T2D [18].
In previous studies, we also reported a brain metabolic dysfunc-
tion in chronic T2D per se, given by the lower membrane potential
and energy levels in adult GK rat brain synaptosomes [74]. In this
regard, since 1) several metabolic partners are involved in neuronal
energy supply and 2) neurons are extremely susceptible to changes in
mitochondrial structure, localization and function thatmay limit energy
production [18,109], mitochondria is increasingly recognized as a
crucial participant in diabetes-related metabolic impairment and its
long-term complications affecting CNS. As such, we recently reported
that both sucrose-treated mice and 3xTg-AD mice (a model of AD)
were highly enriched in swollen brain mitochondria, with disrupted
mitochondrial membranes and cristae [7]. Similarly, Schmeichel et al.
[110] reported structural abnormalities in mitochondria from both
cultured dorsal root ganglion neurons submitted to high glucose levels
or from chronically T1D STZ rats, with cultured neurons showing mito-
chondrial fragmentation/ﬁssion. Additionally, it has been suggested
that an upregulation of DRP1 (a mitochondrial ﬁssion protein) at the
initial phase could start a protective ﬁssion event that could be followed
afterwards by the activation of Bim and Bax and apoptosis [111]. Sur-
prisingly, Edwards et al. [112] showed recently that hyperglycemia
could promote mitochondrial biogenesis in dorsal root ganglion from
diabetic mice, probably resulting (at least partially) from the formation
of small, fragmented mitochondria by ﬁssion. Accordingly, these au-
thors also reported a hyperglycemia-induced increase in DRP1 levels
and that inhibition of DRP1-induced fragmentation in vitro was
neuroprotective against hyperglycemic damage [112].
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strated to be caused by inherited defects in mitochondrial DNA [113].
Moreover, our results in GK rat brain were (at least partially) explained
by a dysfunctional mitochondrial electron transfer chain, further aggra-
vated by aging and/or Aβ incubation in T2D [114]. Accordingly, in a very
recent study, Carvalho et al. [7] observed that a dysfunctional respirato-
ry chain and phosphorylation system in brain mitochondria from both
sucrose-treated and 3xTg-AD mice underlined an ATP deﬁcit, as also
occurs in mitochondria from human AD platelets [115] and from brains
(especially hippocampus and cortex) of other AD mouse models [116].
We also reported that brain mitochondria from chronically T1D rats
(12 weeks after induction of diabetes with STZ), 3xTg-AD and sucrose-
treated mice presented a lower capacity to accumulate and retain
calcium (Ca2+) [7,117]. And Mastrocola et al. [118] proposed that
diabetes-induced nitrosylation or protein thiol stimulates brain mito-
chondrial nitric oxide synthase (NOS) activity, thus increasing nitric
oxide (NO•) levels and inhibiting mitochondrial complexes III and IV
and ATP synthase. As a result, ATP production is hampered and mito-
chondrial membrane potential collapses, leading to mitochondrial
permeability transition pore (mPTP) opening and, ultimately, cell
death [118]. The subsequent loss of synapses and synaptic function
may in turn lead to cognitive decline [119]. Mitochondrial relevance in
T2D is further emphasized by the involvement of human mitochondrial
DNA (mtDNA) mutations and deletions of speciﬁc mitochondrial genes
in dampening of oxidative phosphorylation in pancreatic β-cells from
animal models and in diabetes onset [120].
Overall, these ﬁndings emphasize the role of mitochondrial
dysfunction as a link between (pre)diabetes and AD. Nevertheless, things
may not be as linear as expected, since Seaquist et al. [71] failed to
observe changes in glucose transport upon short-term hyperglycemia.
1.1.3. Involvement of oxidative stress in T2D-mediated CNS lesion
Since mitochondria are also crucial in intracellular Ca2+ buffering
and in the generation of reactive oxygen species (ROS), and the brain
is highly susceptible to oxidative stress-induced damage [7], it is not
surprising that T2D creates a deleterious vicious cycle in brain, involv-
ing metabolic/mitochondrial dysfunction and/or oxidative stress and,
thus, chronically affecting CNS [109,114,121–123]. Interestingly, our
previous studies reported an increase in plasma and brain vitamin E
levels in adult T2D GK rats [124]. Additionally, the antioxidant coen-
zyme CoQ10 [121] and insulin [122] counteracted the deleterious ef-
fects of T2D and T1D in rat brain mitochondria, further highlighting
the importance of metabolic/mitochondrial dysfunction and oxida-
tive stress crosstalk in CNS. We also demonstrated a decrement in co-
enzyme CoQ9 levels in STZ rat brain mitochondria, suggesting that
diabetes-related brain oxidative damage may also arise from impaired
antioxidant mechanisms [122]. Similarly, Fernyhough et al. [125] de-
scribed that increased ROS formation, lipid oxidation and protein
nitrosylation in both T1D and T2D animal models were accompanied by
decreased antioxidant defenses (e.g., glutathione and ascorbate). There-
fore, Frisardi et al. [126] proposed that, similarly to Aβ, neurotoxicity in-
duced by hyperglycemia may arise not only from high glucose levels,
but also from the increased formation of reactive oxygen and nitrogen
species and subsequent oxidative stress. This hypothesis was further
supported by our recent observations that increased mitochondrial ROS
production in sucrose-treated and 3xTg-AD mice brains was correlated
with a decrease in antioxidant defenses [7]. More speciﬁcally, both mito-
chondrial aconitase (highly sensitive to superoxide [127] and inhibited
upon neurodegeneration [128]) and glutathione reductase activities
were decreased in both rodent models. Conversely, glutathione peroxi-
dase activity was stimulated under these conditions. As a result, gluta-
thione levels were reduced in these animals, in accordance with other
studies [118,129,130]. The decrement in vitamin E levels in both AD
and T2D mouse brain, and increased manganese superoxide dismutase
activity were consistent with increased levels in hydrogen peroxide [7]
andwith other studies performed in plasma fromdiabetic [131] and ADpatients [132], as well as with evidence from the Tg2576 mouse model
for AD [133]. Interestingly, this rise in mitochondrial oxidative stress in
brains from both sucrose-treated and 3xTg-AD mice was correlated
with an increased susceptibility to mPTP opening, as previously de-
scribed by Kowaltowski et al. [134].
The involvement of oxidative stress in T2D-mediated brain damage
is further complicated by the fact that it may also arise independently
from metabolic/mitochondrial impairment. Nevertheless, the contro-
versy remains on which appears ﬁrst as disease progresses. Indeed, ox-
idative stress may originate from several other deleteriousmechanisms
associated with chronic hyperglycemia, including AGEs formation,
glucose autoxidation, endoplasmic reticulum stress, and impaired anti-
oxidant defenses, culminating in caspase-dependent neuronal death
[135–137]. In this regard, it has been suggested that oxidative stress
could be a major link in T1D-mediated apoptosis, since T1D animal
models displayed increased hippocampal labeling with speciﬁc
apoptotic markers (e.g. TUNEL staining, Fas and Bax expression,
cytosolic apoptosis inducing factor (AIF), caspases-3 and −12 ex-
pression and activity) and 8-hydroxy-2′-deoxyguanosine (8-OHdG,
a marker for oxidative stress) compared with T2D rats [136]. This
was also correlated with a lower neuronal density in hippocampi
from T1D than in T2D animals [136]. Similar pro-apoptotic effects
were described by other authors in dorsal root ganglion neurons
from diabetic rats [135,138].
1.1.4. Other pathophysiological mechanisms
1.1.4.1. AGEs/RAGE. Other important biochemical players in this intri-
cate puzzle are AGEs, whose abnormal formation and accumulation
occur during normal brain aging, being accelerated by diabetes
[139]. Indeed, studies reported an increased expression of the recep-
tor for AGEs (RAGE) in neurons and glia from cognitively-affected di-
abetic mice [17]. Accordingly, interaction between AGEs and RAGE
has been shown to promote ROS formation, widely described as an
early damaging event in AD pathology [140]. Conversely, RAGE null
diabetic mice were less susceptible to neurodegeneration than wild
type diabetic mice [17]. Additionally, Girones et al. [141] observed
that brain slices from post-mortem diabetic AD patients were more
immunolabelled against AGEs than those from non-diabetic AD
subjects and, more recently, Bruehl et al. [20] suggested that loss of
hippocampal volume in T2D could be mediated by those AGEs.
Furthermore, detection of AGEs in vascular walls, lipoproteins and
lipid constituents were correlated with the development of macro-
and microangiopathy and amyloidogenesis [142].
1.1.4.2. Impaired neurotransmission. Given that glucose is also crucial
for the brain maintenance of amino acid pool [143–145], it is not
surprising that diabetes also impairs neurotransmission [146]. In
fact, as previously discussed, neurotransmission is highly dependent
on mitochondrial function, due to the massive energy-demanding
mechanisms involved in neurotransmitter synthesis and removal
[18,147,148]. Therefore, a crosstalk between mitochondrial dysfunc-
tion, oxidative stress and abnormal excitatory neurotransmitter release
has been recently proposed to underlie the cognitive dysfunction
reported in T1D patients under insulin therapy [146]. Accordingly, we
and others previously showed a decrease in GABA levels in T1D STZ rat
and in insulin-induced hypoglycemic cortical synaptosomes [146], as
well as in plasma from T2D patients and individuals with impaired
glucose tolerance [149]. This, together with increased Ca2+-independent
release in glutamate, suggests that neuronal dysfunction under hypogly-
cemia and/or untreated hyperglycemia in ratsmay also arise fromapath-
ological release of excitatory cytoplasmic amino acids [146]. However,
this was not mirrored in treated T2D rat brain synaptosomes, where
exogenous insulin administration modulated GABA and/or glutamate
transport under oxidative stress and/or T2D [74,75]. Additionally, others
showed that hyperglycemia impaired glutamate release upon ischemia/
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and that glutamate afﬁnity for AMPA (but not NMDA receptors) was de-
creased in STZ rat brain [153]. Taurine and GABA transport was also
shown to increase in diabetic rat retina and retinal pigment epithelium
[154]. According to Guyot et al. [150], the increase in extracellular GABA
and in the density of GABAA receptors upon insulin treatment in T1D
rats may constitute a protective mechanism against cytotoxic effects of
released excitatory amino acids.
1.1.4.3. Decreased neurogenesis. From the above-mentioned, it is not
surprising that diabetes compromises synaptic plasticity and learning
potential. However, in the last years, it has been described that
neurogenesis is also affected in both T1D [155–157] and T2D rodent
models [158], as well as in hippocampus from high-fat fed rodents
(a condition that accelerates diabetes) [159]. More speciﬁcally, Lang
et al. [158] reported that, despite an initial increase in progenitor
cell proliferation in the neurogenic regions of the adult GK rat brain,
their survival was severely affected. According to the authors, this
might constitute a feed-forward mechanism to increase proliferation
in a vain attempt to maintain the steady-state formation of new neu-
rons, thus compensating for the increased CNS cell death in the early
phase of disease. But, as the animals' age, the long-term survival and
the number of progenitor cells decrease in dentate gyrus [158]. Accord-
ingly, if diabetes remains untreated, the newborn cells cannot survive
and differentiate into fully functional neurons [160]. Although the mech-
anisms involved herein remain unclear, diabetes-associated chronic in-
ﬂammation and oxidative stress may be involved [161–164]. Moreover,
Lang et al. [158] proposed that unresponsiveness to growth factors may
also play a role in this incapacity of newly formed cells to survive upon
T2D. In this perspective, given the disruption of insulin signaling path-
ways in GK rats and the crosstalk between IGF-1 and IR, it is not surpris-
ing that their neural progenitors failed to respond to IGF-1, thus
impairing PI3K/Akt/GSK-3β signaling, widely known to be involved in
cell death [161]. Therefore, the declined learning andmemory in diabetic
patientsmay arise fromhippocampal dysfunction [165], alternatively due
to disruption of neurogenesis [158]. Accordingly, Oitzl et al. [166] showed
that long-term exposure to high levels of corticosterone (as occurs in di-
abetes) impaired learning in animals, whilst maintenance of their physi-
ological levels promoted neurogenesis, restored long-term potentiation
(LTP) and reverted learning deﬁcits upon T2D [156].
1.1.4.4. Recurrent hypoglycemic episodes. Evidences for chronic T2D
damage to CNS mostly involve persistent hyperglycemia-associated le-
sion, leading to the idea that the simple normalization of blood glucose
levels by insulin could protect against those injuries. However, wemust
bear inmind that cognitive dysfunction affecting these patients (aswell
as T1D individuals) may also arise from recurrent hypoglycemic epi-
sodes (the most common side-effect of insulin therapy) [1,167], as in-
creasing evidence demonstrates that these episodes may adversely
affect diabetic CNS [153,168]. For example, hypoglycemia was shown
to affect endogenous levels of metabolites indirectly related with
brain glucose metabolism, by accelerating lipolysis (increasing the for-
mation of highly oxidizable polyunsatured fatty acids) and impairing
protein synthesis, ion homeostasis, andmitochondrial function, leading
to the neuronal dysfunction [54,169] that underlies motor incapacity,
seizures, or cognitive damage, mainly in aged patients [170].
Despite the limited knowledge, hypoglycemia-related neuronal
loss may play a crucial role in permanent diabetic brain damage
[171]. Indeed, rather than the direct result of energy failure, such neu-
ronal death appears to culminate in multiple deleterious events [172].
This further suggests that poor glycemic control may damage brain
areas involved in learning and memory [173], thus limiting the anal-
ysis of insulin and hyperglycemia roles in diabetic brain [11].
Our group showed that, although insulin treatment was able to
protect T1D STZ rat brain against oxidative stress and mitochondrial
dysfunction (either after in vitro mitochondrial exposure to Aβ ornot) [117,122], this was not mirrored upon an acute episode of
insulin-induced hypoglycemia in TD1 rat brain [173], in which in-
creased levels of excitatory neurotransmitters (namely glutamine,
glutamate, aspartate and taurine) and decreased levels of the inhibi-
tory amino acid GABA were observed [146]. Accordingly, McGowan
et al. [174] showed that acute episodes of hypoglycemia increase
brain NMDA receptor binding sites to glutamate. Moreover, Battezzati
et al. [175,176] described that, contrary to healthy individuals, T1D
patients suffering a hypoglycemic–hyperinsulinemic clamp loose the
counter-regulatory response that allows the utilization of excessively
released glutamine as an alternative fuel to glucose, thus presenting
abnormally high levels of this amino acid in plasma. Additionally,
the lower release of GABA upon T1D and the acute hypoglycemia
may further contribute to the severity of neuronal damage [146].
Overall, these results suggest that the increased capacity to release ex-
citatory cytoplasmatic amino acids and/or decreased release of inhibitory
neurotransmitters upon diabetes and hypoglycemia could be related
with increased oxidative stress-related neuronal membrane damage
and cell death, as hypothesized by others [177–179]. Accordingly, a single
acute insulin-induced hypoglycemic episode was shown to exacerbate
the detrimental effects of T1D in brain cortical mitochondria bioenerget-
ics and oxidative status [173].
1.2. Incretins/GLP-1 receptor mimetics
The high prevalence of both diabetes and AD in the increasingly aged
population, together with the strong link between both pathologies and
insulin signaling, fostered the recent search for efﬁcient therapeutic/
preventive strategies against diabetes-related AD, especially among
currently Food and Drug Administration (FDA)-approved anti-diabetic
drugs [180].
1.2.1. Previous anti-T2D drugs with promising neuroprotection features:
what failed?
Amongst the several classes of anti-diabetic drugs, the use of
sulphonylureas to treat T2D patients has declined in the last 20 years,
mostly due to themore efﬁcient combination of therapeutics that target
themultitude of defects associatedwith the pathology [181–183]. Inter-
estingly, the thiazolidinediones (TZD, from the class of anti-T2D drugs,
the peroxisome proliferator-activated receptor-γ (PPARγ) agonists)
rosiglitazone and pioglitazone are known to control neuroinﬂammation
and oxidative stress and to activate STAT3- and Wnt-mediated signal-
ing pathways. This could in turn provide the proper microenvironment
for neural progenitor cells to proliferate and differentiate into mature
neurons in diabetic brain [158,184]. Accordingly, these drugs were
shown to decrease stroke-induced brain damage and neurological
dysfunction in T2D mice [185]. Moreover, as an insulin sensitizer,
rosiglitazone has been proposed to increase insulin signaling, which to-
gether with the decrease of insulin levels, might reduce its competition
withAβ for degradation by IDE, thus lowering Aβ1-42 levels and improv-
ing learning and memory deﬁcits [186]. However, rosiglitazone's and
pioglitazone's side-effects in terms of cardiovascular risk led FDA to
pose some restrictions for TZD prescription and use.
As previously described, insulin has been increasingly studied not
only as an anti-T1D therapy, but also against T2D not controlled by
diet, exercise or oral anti-diabetic agents, and it has been shown to
decrease microvascular complications and mortality in these patients
[187,188]. In fact, it has been increasingly suggested that all diabetic
patients could be insulin treated, independently of disease progres-
sion [187]. Nevertheless, despite the great emphasis on diabetes
care, healthy lifestyle and oral hypoglycemic therapy, as disease pro-
gresses, insulin's beneﬁcial effects may be lost [189]. Therefore, in the
later stages, the use of combined medications with synergistic effects
and that address key pathophysiologic abnormalities of T2D without
serious side-effects may have important advantages.
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Given the failure of other promising anti-T2D approaches, an
increasingly used class of drugs is the incretin/glucagon-like peptide-1
(GLP-1) receptor (GLP-1R) agonists.
Incretins are gastrointestinal hormones, ﬁrst identiﬁed in the
1960s, when an enteral glucose load increased insulin secretion
greater than parenteral administration — the so-called “incretin
effect” [190]. Initially, this differencewas faced as secondary to an addi-
tional stimulus of gastrointestinal or hepatic origin [190]. Then, it was
shown to result from the secretion of GLP-1 and glucose-dependent
insulinotropic polypeptide (GIP) by enteroendocrine K and L cells,
respectively [191], which account for ~70% of the insulin response to
glucose [192].
Despite the decrement in GLP-1 secretion in T2D patients, its
insulinotropic activity remains unaffected, while GIP presents an op-
posite pattern, possibly due to genetic factors [193,194]. Therefore,
GLP-1 has been the primary research target for new T2D treatments
based on incretin [192], namely the several GLP-1R agonists and
dipeptidyl peptidase-4 (DPP-4) inhibitors that are presently used
clinically [189]. In this regard, exogenous administration of GLP-1
was shown to restore incretin physiology in T2D patients [195].
However, circulating GLP-1 has a short half-life, with up to 80%
of it being degraded within 2 min after release by the enzyme
DPP-4 [196,197]. DPP-4 is a ubiquitous aminopeptidase expressed
in, e.g., liver, lung, kidney, endothelium and lymphocytes [191,198].
Besides incretins, DPP-4 has also other substrates, namely other gastro-
intestinal hormones, neuropeptides, cytokines and chemokines [191].
Therefore, several long-acting GLP-1R agonists that mimic the effects
of native GLP-1 and that are more resistant to DPP-4-mediated deg-
radation (with half-lives of 2.4 to 13 h that result in pharmacologic
concentration of GLP-1) have been developed to treat T2D. Further-
more, DPP-4 inhibitors inactivate this enzyme and thus improve
endogenous GLP-1 levels at the upper limit of the normal physiological
range [191,199,200].
Although both GLP-1R agonists and DPP-4 inhibitors effectively
achieved an optimal glucoregulation upon obesity, this required
mostly a sustained receptor-mediated activation of the incretin axis
(which also stimulated β-cell gene expression) [201]. Additionally,
clinical studies comparing drugs from both classes demonstrated
that exenatide or liraglutide (GLP-1R agonists used in T2D treatment
[202]) were more efﬁcient in lowering blood glucose levels upon
hyperglycemia (but not euglycemia), glycated hemoglobin (HbA1C)
and body weight in T2D patients than sitagliptin (a DPP-4 inhibitor)
[2,202,203]. And GLP-1R agonists were also more efﬁcient in reducing
total caloric intake [204]. Contrary to insulin and other oral anti-
diabetic drugs, GLP-1R agonists also minimize the risk of hypoglycemia
and may even improve β-cell function (an important issue, since at the
time of T2D diagnosis, β-cell mass and function are already decreased)
[2]. Nevertheless, in somepatients exenatide and liraglutide also caused
nausea and diarrhea [205,206].
1.2.2.1. The peripheral and brain GLP-1R. GLP-1R are ubiquitously
distributed throughout the organism, especially in pancreas (α- and
β-cells), endothelium, heart, kidney, lung, brain, gastrointestinal
tract and spinal cord [2,203,207–210]. Peripherally, once bound to
its receptor, the endogenous GLP-1 (an incretin of 30 amino acid
length) may exert multiple effects, including stimulation of glucose-
dependent insulin secretion, and suppression of glucagon secretion,
appetite and food intake and gastric emptying delay. And it also stim-
ulates β-cell proliferation in preclinical models [203,211], as well as in
both T1D and T2D patients [192,212–214]. As previously described,
the most well-known role of incretins is their glucose-dependent
insulinotropic effect, with insulin secretion decreasing as blood
glucose levels become normal [2]. Despite the scarce and somehow
controversial information, hampered GLP-1-mediated insulinsecretion (a state of GLP-1 resistance) was detected in human sub-
jects with diabetes, impaired glucose tolerance or insulin resistance
[215–218], probably due to hyperglycemia per se and/or the genetic
background [218]. Moreover, GLP-1 resistance may also arise from
the decrement on the incretin content after a mixed meal in people
suffering from T2D or impaired glucose tolerance [219,220], especially
potentiated in the late-phase response [221]. However, other studies
failed to report signiﬁcant changes in fasting GLP-1 levels in humans
with T2D or impaired glucose tolerance [193,222–225].
In CNS, GLP-1 expression occurs in the hypothalamus, cortex,
hippocampus, striatum, substantia nigra, brain stem and subventricular
zone (one of the neurogenesis areas in the adult brain) [207–209].
Under physiological conditions, GLP-1R expression is primarily conﬁned
to large output neurons, epitomized by pyramidal and dentate granule
neurons, as well as Purkinje cells (where it localizes to dendrites
and/or near synapses) [209]. Surprisingly, the detection of GLP-1R
mRNA and protein in the brain of Zucker rats suggested that these
receptors may be also synthesized in loco [226].
1.2.2.2. Functions of GLP-1R agonists in (diabetic) brain and periphery.
Besides the above-mentioned actions of GLP-1 mimetics, therapies
involving these drugs were shown to decrease food intake and body
weight, and to stimulate insulin secretion and gastric emptying
more efﬁciently than DPP-4 inhibitors in rodent models [227], as
well as in high fat-fed mice with glucose intolerance features [201].
Importantly, peripheral GLP-1 can cross the BBB by simple diffusion
[228], gaining access to paraventricular nucleus and directly activating
glucocorticoid formation without increasing glucose levels afterwards
[229]. However, the mechanisms involved herein are not completely un-
derstood. Similarly, centrally-acting GLP-1 analogs (e.g. the GLP-1(7–36)
amide) modulate food intake via neurons from the arcuate nucleus and
circumventricular organs [226]. The earliest endocrine mechanism
activated by food intake is the insulinotropic incretin effect and involves
the secretion of GIP, followed immediately by that of the potent
insulinotropic GLP-1 (both in T2D and non-diabetic individuals), culmi-
nating in increased blood insulin levels to deal with the post-prandial
rise in glycemia [230]. However, it has been recently described that
GLP-1 action in CNS is blunted in high-fat fed, insulin-resistant mice
[231].
GLP-1R agonists were also able to enhance synaptic plasticity,
strengthen LTP and improving cognitive performance [232–234].
This was further conﬁrmed in mice overexpressing GLP-1R that
showed improved learning skills [235], whilst knockout mice for
GLP-1R had impaired memory formation [236].
Importantly, both peripherally-administered GLP-1 and its ana-
logs have been reported to readily cross the BBB and reach the CNS
[237,238], whereby they act as neurotrophic factors, inducing neurite
outgrowth [239] and tyrosine hydroxylase expression [240,241], as
well as anti-inﬂammatory [242–244] and as neuroprotective agents
[245,246]. As described previously in this section, both peripherally-
and centrally-administered GLP-1 analogs and agonists have potent,
long-lasting anorexic effects (e.g., exenatide-induced weight loss
was shown to persist for at least 2 years) [247–249]. Despite some
controversy on the mechanisms involved herein, it has been hypoth-
esized that nausea, decreased gastric emptying and increased satiety
associated with GLP-1 mimetics could explain the decreased oral
intake reported under such therapies [247]. Concerning the role of
nausea, despite no signiﬁcant correlation between nausea and de-
creased body weight were reported [247], several studies showed
that individuals treated with exenatide or liraglutide who had nausea
for several days also tended to lose more weight [248]. Alternatively,
the GLP-1 agonist-associated ileal brake (and subsequent decreased
gastric emptying) could also account for lowered food intake, proba-
bly via reduction of the initial postprandial increase in plasma glucose
[250]. It is worth mentioning that ileal brake is the primary neuronal
and hormonal inhibitory feedback mechanism that regulates the
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ent digestion and absorption [247]. GLP-1 mimetics have been also
described to promote satiety feelings, thus decreasing sensation of
hunger and subsequent food intake [247].
From the above-mentioned, it is not difﬁcult to understand that, if
several questions remain pending on the physiological mechanisms
by which GLP-1 mimetics inhibit food intake and decrease body
weight, the subcellular/molecular mechanisms involved herein
remain even less understood. In this regard, some evidence points
towards a hypothalamic involvement (at least partially) in both CNS-
and peripherally-administered GLP-1 decrease in caloric intake and
body weight [247]. This hypothesis is supported by reports showing
that: 1) GLP-1 synthesis occurs within the nucleus of the solitary tract
neurons, which are known to innervate the hypothalamus [248], 2) in-
jection of GLP-1 in the third ventricle promoted neuronal activation
of paraventricular and arcuate nuclei of the hypothalamus, highly in-
volved in energy balance regulation [248], and 3) GLP-1 and exenatide
decreased ghrelin levels (a potent orexigenic hormone) [230] and may
also act on other neuronal hypothalamic populations (e.g. POMC neu-
rons) or crosstalk with other anorexigenic hormones (namely leptin),
thus indirectly activating anorexic circuits [248]. However, the extent
of the interaction between ghrelin and other satiety factors and weight
loss remains unknown. Another striking evidence for such hypothalamic
involvement in decreased food intake/body weight was that GLP-1
mimetics promoted hypothalamic neurogenesis, thereby increasing the
number of healthy, GLP-1-responsive neurons involved in long-term
glucose and body weight homeostasis [251].
Alternatively, body weight loss under GLP-1 treatment could be
due to an increase in energy expenditure. In fact, Pannacciulli et al.
[252] reported a correlation between higher fasting GLP-1 levels
and higher resting energy expenditure and fat oxidation. Accordingly,
GLP-1 infusion also promoted energy expenditure in healthy individ-
uals [253], being abolished by constant insulin levels and suggesting
an indirect effect on energy expenditure [248], probably mediated
by a stimulation of sympathetic activity [254,255]. However, the
mechanisms involved herein remain unknown and both human and ro-
dent studies have produced conﬂicting results [248]. It is also worth
mentioning the study by Perley and Kipnis [256] showing that, despite
no changes in fat oxidation, a similar dose of GLP-1 infusion reduced
carbohydrate oxidation and diet-induced thermogenesis.
As it is not our goal to extensively revise the role of all incretin-based
therapies in this paper, we will focus mainly in the CNS effects of the
most well-studied anti-T2D drugs of this class, exenatide (exendin-4)
and liraglutide.
1.2.2.3. Exendin-4 in CNS. Exenatide is a synthetic injectable,
DPP-4-resistant GLP-1R agonist derived from exendin-4, which is in
turn a peptide derived from the saliva of the Gila monster, Heloderma
suspectum [191,257]. Exendin-4 shares a 53% amino acid sequence
identity with human GLP-1 [258] and the glucose-lowering potency
of exenatide is ~5500-fold greater than that of endogenous GLP-1
[191,257].
Exendin-4 has been approved by the FDA in 2005, being indicated as
an adjunct to diet and exercise to improve glycemic control in T2D
adults [2], either as monotherapy or in combination with other oral
anti-T2D agents (e.g. metformin, sulphonylureas and TZDs), but not
with insulin [195]. Importantly, this GLP-1R agonist is stable in blood
and most of the injected peptide immediately reaches the brain intact
(rather than being trapped in BBB endothelial cells) [230,237]. This is
not surprising, given exendin-4 high lipophilicity and independency
from circumventricular organs to be transported into the CNS, being
also insensitive to food deprivation for 24 h [237]. Once bound to
GLP-1R (a 7-transmembrane protein that belongs to the class B1
G-protein-coupled receptor family) [259], exendin-4 (as GLP-1) initi-
ates a signaling cascade that activates adenylyl cyclase, increasing
cAMP levels (in a dose-dependent manner) which, in turn, interactswith several downstream molecules, such as protein kinase A (PKA),
PI3K and mitogen-activated protein kinase (MAPK) [203,260,261].
Recently, Li et al. [210] showed that PKA- and PI3K-mediated path-
ways are involved in the neurotrophic and neuroprotective roles of
exendin-4 and GLP-1 in cultured neurons [240,241], while MAPK sig-
naling plays a supportive role [239]. In 2000, Al-Barazanji et al. [262]
showed that chronic exendin-4 therapy reduced body weight in both
obese and lean Zucker rats by reducing food intake, suggesting a decre-
ment inmetabolic rate. Similar results were obtained upon direct injec-
tion of exendin-4 into the brain in non-obese animals [263,264]. More
recently, Hayes et al. [260] described that such a decrease in food intake
and body weight associated with exendin-4 was mediated by PKA and
MAPK signaling. More speciﬁcally, these effects of exendin-4 were pos-
sible due to the coordinated PKA-induced suppressionof AMP-activated
protein kinase (AMPK) and p70S6 kinase (p70S6K), aswell as to the ac-
tivation of MAPK in hindbrain, thus representing a possible efﬁcient
anti-obesity approach [260]. On the other hand, MAPK-independent
pathways and growth factor-dependent Ser/threonine (Thr) Akt have
been also described [245], as well as an Epac-mediated pathway
[265]. In this perspective, the differentially-modiﬁed GLP-1 signaling
in differentmodels of dietary obesitymay explain the conﬂicting results
described in obese humans [266–269], with some studies reporting a
suppression of food intake in lean and obese humans upon GLP-1 ad-
ministration [270,271]. Additionally, a central GLP-1-mediated neuro-
nal activation of brainstem and hypothalamic structures potentially
involved in conveying satiety signals may be essential to attenuate the
perceived orosensory reward of palatable food and reduce food intake
initiated by a meal [263,264]. As a result, excessive consumption of
high dietary fat may impair the anorexigenic gut–brain feedback, stim-
ulating the feeling of reward upon the intake of sweetened taste food
[263]. In this regard, successful anti-obesity therapies may involve an
inhibition of the desire to overconsume palatable and obesogenic
foods (e.g. by improving hypothalamic neuronal recognition of
increased glycemia after a meal, thereby accelerating the state of
fullness), as well as re-establishment of anorexigenic signals [263,226]
and activation of the enteric neurons [272]. On one hand, metabolites
arising from hypothalamic neuronal glucose oxidation may be involved
in satiety-related signaling pathways; on the other hand, hypothalamic
receptors may control energy expenditure via modulation of CNS and
peripheral action of leptin, insulin, glucocorticoids, galanin or NPY
[226].
Several authors observed that subcutaneous exendin-4 adminis-
tration also decreased the hypothalamic content of serotonin and
norepinephrine in obese and lean rats, two neurotransmitters in-
volved in the regulation of food intake [226,263]. Recently, Darsalia
et al. [273] hypothesized that exendin-4 neuroprotection may occur
via either GLP-1R-dependent or –independent pathways, in a
dose-dependent manner.
Similarly to native GLP-1, peripheral exenatide was shown to
stimulate glucose-dependent, ﬁrst- and second-phase insulin secre-
tion [274], inhibit glucagon secretion, slow gastric emptying, and re-
duce appetite/caloric intake, thus promoting weight loss [275].
Conversely, recent evidence showed that the anti-stroke efﬁcacy of
GLP-1R activation in non-diabetic mice was not accompanied by
changes in insulin secretion, suggesting that its CNS effects are not
due to changes in glycemia [276].
In preclinical and clinical studies exenatide was also demonstrated
to promote cellular neurogenesis and proliferation, and to inhibit ap-
optotic death, increasing β-cell mass [191,277] and function
[274,278]. Importantly, the anti-apoptotic effect of exendin-4 de-
scribed in clonal insulinoma (INS-1E) cell lines treated with human
islet amyloid polypeptide (hIAPP) was mediated (at least partially)
by Akt pathway, since the peptide rescued treated cells from
hIAPP-induced FOXO1, inhibition of pdx-1 translocation into the nu-
cleus and activation of caspase-3 (known mediators of apoptotic cell
death), recovering cell mass [279]. Furthermore, as Akt signaling has
535A.I. Duarte et al. / Biochimica et Biophysica Acta 1832 (2013) 527–541been intimately coupled with mitochondrial biogenesis, it is not sur-
prising that exendin-4 also restored the expression of mitochondrial
DNA-encoded genes, number of mitochondria and activity of succi-
nate dehydrogenase (indicative of improved mitochondrial function)
under such damaging conditions [279]. Other clinical studies reported
a long-lasting exenatide-mediated HbA1c and post-prandial glucose
lowering in T2D patients, with some effects maintained for 3 years
[195,278,280]. Similar exendin-4-mediated reduction in glycemia
was reported in T2D GK rats [273].
Similarly to the anti-apoptotic effect of exendin-4 on pancreatic
β-cells, GLP-1 analogs also protected cultured neurons against oxida-
tive stress-, hypoxia- and trophic factor withdrawal-associated apopto-
sis [239,240,281]. Accordingly, in vivo studies reported a reduction in
brain damage and improved functional outcome upon treatment with
GLP-1 analogs after stroke [240,276], aswell as in several animalmodels
of PD [240,243,282,283] andHuntington's disease (HD) [246], peripher-
al neuropathy [284] and in AD alone [281,285–287] or in association
with T2D [261]. In fact, exendin-4 is already being assessed as a new
therapeutic strategy against PD and AD.
Importantly, those neuroprotective effects of GLP-1 analogs were
also accompanied by increased neurogenesis, as given by the increase
in neuronal progenitor cells in the brain of GLP-1 agonist-treated
animals, in the number of surviving neurons in stroke-damaged stria-
tum and cortex and in increased neurogenesis in an experimental
model of PD [234,273,282,283,285]. In a very recent study, Li et al.
[210] observed that exendin-4 has neuroprotective and neurotrophic
properties in the superoxide dismutase-1 (SOD1) models (both
cellular and animal models) of amyotrophic lateral sclerosis (ALS).
These beneﬁcial effects for motor neurons included glucose tolerance
amelioration, preservation of lumbar spinal cord structure and neuron
density, restoration of speciﬁc spinal cord markers and running behav-
ior, aswell as a reduction in apoptosis in spinal cord and in astrocytosis/
microglia activation (at both presymptomatic and end stage disease,
thus decreasing proinﬂammatory cytokine production) [210,242]. Ad-
ditionally, exendin-4 protected neuronal cell lines against oxidative
stress [180,288], ameliorated staurosporine-induced apoptosis (known
to be mediated by active caspase-3 and increased Bax expression) upon
trophic factor withdrawal [210,240,241], increased tyrosine hydroxylase
expression (a dopaminergic marker) in dopaminergic neurons [240], as
well as a cholinergic marker (choline acetyltransferase) and cell viabil-
ity [210]. Exendin-4 was also neuroprotective against glutamate
excitotoxicity [286]. Interestingly, its protective effect against high glu-
cose levels was mediated by the PI3K pathway in PC12 cells [180].
Exendin-4 also reduced the in vitro generation of Aβ in cultured neu-
rons under both euglycemic and hyperglycemic conditions and in
mouse brain, protected against Aβ-associated hippocampal neuronal
death and rescued learning and memory performance in ICV-STZ
rats (a model of sporadic AD) [180,261,281,287]. These effects were
correlated with protection against hippocampal degeneration and
P-Tau, probably via downregulation of GSK-3β [180,246,281,287].
Surprisingly, Kim et al. [261] reported that exendin-4 was able to
fully reverse the massive increase in soluble Aβ levels in the brains of
3xTg-AD female mice injected with STZ. Similarly, the neuroprotective
effect of exendin-4 was recently described also in STZ rodents (which
have been also associated with AD due to increased brain levels of Aβ)
[281]. Given these results and that female gender is a well-known risk
factor for AD, exendin-4 offers a promising therapeutic avenue against
this pathology, providing preclinical support for translational studies
in diabetic and/or AD patients [261].
Interestingly, given its role in body weight reduction, the protec-
tive effect of exendin-4 was also extended to high fat-fed mice
(which are also more prone to T2D). Herein, the GLP-1R agonist
was able to improve metabolic control, learning and memory, rescue
LTP and hippocampal synaptic plasticity, thus improving cognitive
function upon obesity [289], and may thus constitute a promising
therapy against obesity.Concerning anti-hyperglycemic agents, the adverse effects (e.g. gas-
trointestinal upset, hypoglycemia and weight gain) associated with
their use can limit successful glycemicmanagement, but aremostly tran-
sient, mild to moderate and prevalent at the treatment initiation
[195,290]. Moreover, a onceweekly formulation of exenatide is in clinical
development and involves its encapsulationwithin biodegradablemicro-
spheres of poly(D,L-lactic-co-glycolic acid), to allow for gradual and
controlled drug delivery [291], thus representing a huge advantage com-
pared to the current twice daily regimen [292,293]. Ongoing studies re-
vealed promising results of this new formulation for exenatide therapy
[2].1.2.2.4. Liraglutide in CNS. Another recently approved anti-T2D GLP-1R
agonist therapy is liraglutide. This has the advantage of only requiring
a once daily administration to improve glycemic control in T2D
adults, together with diet and exercise [2]. Similarly to exenatide,
liraglutide can be used as monotherapy or in combination with met-
formin, a sulphonylurea or a TZD to treat T2D, but not with insulin [2].
Liraglutide was formed by the replacement of lysine 34 of human
GLP-1 with arginine, and by the attachment of a C16 fatty acid chain
at position 26, using a γ-glutamic acid spacer, thus maintaining ~97%
of the native GLP-1 sequence. This also facilitates albumin-binding
and DPP-4 resistance, thereby allowing a half-life of ~13 h and the
single daily dosage described [294]. Similarly to native GLP-1 and
exenatide, liraglutide binding to GLP-1R activates adenylyl cyclase and
upregulates cAMP/PKA signaling pathways [295], promoting the
cAMP response element-binding (CREB) phosphorylation and nuclear
gene transcription [296]. As a GLP-1R agonist, “traditional” liraglutide
functions include stimulation of glucose-dependent insulin secretion,
weight loss, satiety (decreasing food intake) and slowing gastric empty-
ing [294]. Therefore, and similarly to exendin-4, liraglutide has been
also proposed to be efﬁcient in obesity treatment, in part due to its
resistance to DPP-4-mediated degradation and subsequent longer
half-life (and functional activity) [232,260]. Interestingly, liraglutide
was shown to be more effective than exenatide in decreasing HbA1c,
with less nausea and hypoglycemia episodes. Nevertheless, side-
effects were more severe with liraglutide than exenatide [2].
Concerning the role of liraglutide in CNS, available knowledge re-
mains limited. At this respect, some authors described that, similarly
to exendin-4, liraglutide also increased proliferation of progenitor
cells in the subgranular zone of the dentate gyrus in high fat-fed
mice (a model of T2D), as well as in non-obese mice [160,297]. This
increase in new neurons is of the outmost interest, as it may have po-
tential beneﬁcial regenerative effects in neurodegenerative diseases,
such as AD [298,299]. In other study, peripherally-injected liraglutide
was also able to decrease plaque formation, rescue memory and
cognitive performance, promote hippocampal synaptic plasticity
and decrease inﬂammation in high fat-fed mice and in the presenilin
1 (APP/PS1) mouse model of AD [160,285,300], similarly to other re-
ports [289,300]. Others demonstrated recently that intrahippocampal
injection of liraglutide in rats also protects against Aβ25–35-induced
impairment in learning and memory, in a dose-dependent manner,
supporting the idea that liraglutide could be probably an important
player in the prevention or treatment of memory loss in AD patients
[296]. However, clinical trials involving AD patients are essential
to test this hypothesis. Interestingly, these authors also reported
that pretreatment with liraglutide prevented Aβ25–35-induced
impairment of LTP, probably via a rapid and transient upregulation
of intracellular cAMP levels (as occurs in astrocytes and hypothalamic
neurons [242,251]), and subsequent cAMP/PKA signaling pathways,
thereby improving learning and memory. These results were consis-
tent with others obtained with lixisenatide [297], another GLP-1R
agonist that will be released soon onto the market [301]. Alternatively,
GLP-1R stimulation could also activate growth factor-like signaling
cascade [232], increase dendritic sprouting and neuronal regeneration
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[245,287].
In a recently published study, Porter et al. [302] showed that
liraglutide also rescued LTP, plasma glucose, insulin levels, food in-
take in adult obese diabetic (ob/ob) mice (that also suffer from insulin
resistance). According to these authors, liraglutide's beneﬁcial effects
on metabolic control and synaptic plasticity appear to be at least
partially-mediated by increased Mash1 expression, which has been
also suggested to improve hippocampal neurogenesis and cell survival
in these mice.
As exendin-4, peripheral liraglutide also suppressed food intake, via
activation of GLP-1R from vagal afferents, as well as via CNS-mediated
effects [303], supporting the idea that this peptide may cross BBB. In-
deed, in a very recent study, Hunter and Holscher [297] demonstrated
that both liraglutide and lixisenatide were able to cross the BBB, in
a highly regulated and time- and dose-dependent fashion, thereby
activating CNC GLP-1R. According to these authors, such transport
may shutdown upon supraphysiologic doses. However, the dose of
lixisenatide required for this transport and to activate GLP-1R appears
to be lower than that of liraglutide [297].
Importantly, exendin-4 is currently on themarket as a T2D treatment
and is injected peripherally twice-daily, while liraglutide is injected
peripherally once daily [304]. Lixisenatide is under development to be
used as a once-daily treatment for T2D [301]. Interestingly, these
drugs can be also taken by non-diabetic people, as they only affect
blood sugar levels in a hyperglycemia situation [305].
2. Conclusion
In the last years, the T2D epidemic emerged as an increasingly
social and economic challenge, mostly in under development countries.
Despite the etiological complexity of T2D (involving a cluster of several
risk factors, mostly associated with modern lifestyle) and the limited
knowledge on the molecular mechanisms involved herein, it has been
widely proposed that neurodegeneration/cell death associated with
chronic T2Dmay result from a complex interaction between the pathol-
ogy and brain aging. As a result, brain structural and functional changesFig. 1. Molecular mechanisms underlying long-term T2D in CNS and AD. Increasing evi-
dence demonstrates that T2D is a risk factor for AD and that AD patients are more prone
to T2D. Although themolecular mechanisms involved herein are not completely clariﬁed,
it has been suggested that a complex interaction between T2D and brain agingmay occur,
involving e.g. a decrease in brain insulin (Ins) levels and/or action (Ins receptor, IR), an im-
pairment in brain glucose uptake and metabolism (despite peripheral hyperglycemia),
mitochondrial dysfunction and oxidative stress (ROS). Increased advanced glycation
endproducts (AGEs) formation and interaction with their receptors (RAGE) and impaired
neurotransmission may be also involved, decreasing neurogenesis and promoting
neurodegeneration/death, which underlie brain atrophy and cognitive dysfunction seen
in both pathologies. Interestingly, GLP-1 mimetics have been recently demonstrated to
exert neuroprotective/neurogenesis effects against deleterious conditions (e.g. AD and
PD models), besides their well-known insulinotropic and anorexigenic properties.may arise, culminating in cognitive dysfunction underlying dementia-
type disorders (e.g. AD) (Fig. 1). Indeed, AD has been hypothesized as
the “type 3 diabetes” affecting the brain.
In summary, as the success against long-term complications of T2D
rely mostly on early diagnosis, healthy lifestyle and efﬁcient therapies,
given the success of several in vitro and in vivo studies using GLP-1 mi-
metics, it is tempting to hypothesize that, together with improvement
of insulin secretion, these GLP-1 analogs may overcome an increasingly
recognized GLP-1-resistant state occurring in T2D, obesity or AD, thus
constituting a potential therapy against cognitive dysfunction occurring
under these circumstances (Fig. 1). However, the results from the ongo-
ing clinical trials (and further basic research) will be essential to improve
knowledge on this subject.Acknowledgements
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